Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2019 Feb 11;12(2):e223528.
doi: 10.1136/bcr-2017-223528.

Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo

Leo E Reap  1 , Cassandra Rodd  2 , Jose Larios  3 , Michael Marshall  3
Affiliations
Case Reports

Hydrochlorothizide-induced acute generalised exanthematous pustulosis presenting with bilateral periorbital impetigo

Leo E Reap et al. BMJ Case Rep. .

Abstract

Acute generalised exanthematous pustulosis (AGEP) is a severe cutaneous adverse reaction characterised by the appearance of erythematous plaques and papules with overlying non-follicular pinpoint pustules. Drugs are the cause of AGEP in approximately 90% of cases. The most common causes include anti-infective agents (aminopenicillins, quinolones, antibacterial sulfonamides and terbinafine), antimalarials and diltiazem. To the best of our knowledge, to date there has only been one report of hydrochlorothiazide-induced AGEP. There has never been a case report of losartan-induced AGEP. Here, we present a case of AGEP that is the second case purportedly caused by hydrochlorothiazide.

Keywords: cardiovascular system; dermatology; drug interactions unwanted effects / adverse reactions; drugs and medicines.

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Figures

Figure 1
Figure 1
Acute generalised exanthematous pustulosis with periorbital impetigo and facial desquamation.
Figure 2
Figure 2
Confluent patchy erythema, desquamation and pustule formation extending along the dorsum of the arm consistent with acute generalised exanthematous pustulosis.
Figure 3
Figure 3
On 2-week follow-up after discontinuation, demonstrating complete resolution.
Figure 4
Figure 4
Minimal residual desquamation present with healthy new skin developing beneath.
See this image and copyright information in PMC

References

    1. Szatkowski J, Schwartz RA. Acute generalized exanthematous pustulosis (AGEP): A review and update. J Am Acad Dermatol 2015;73:843–8. 10.1016/j.jaad.2015.07.017 - DOI - PubMed
    1. Sidoroff A, Halevy S, Bavinck JN, et al. . Acute generalized exanthematous pustulosis (AGEP)--a clinical reaction pattern. J Cutan Pathol 2001;28:113–9. 10.1034/j.1600-0560.2001.028003113.x - DOI - PubMed
    1. Kostopoulos TC, Krishna SM, Brinster NK, et al. . Acute generalized exanthematous pustulosis: atypical presentations and outcomes. J Eur Acad Dermatol Venereol 2015;29:209–14. 10.1111/jdv.12721 - DOI - PubMed
    1. Murad A, Murphy A. Cutaneous vasculitis overlap with acute generalised exanthematous pustulosis (AGEP). Case Reports 2014;17. - PMC - PubMed
    1. Hoetzenecker W, Nägeli M, Mehra ET, et al. . Adverse cutaneous drug eruptions: current understanding. Semin Immunopathol 2016;38:75–86. 10.1007/s00281-015-0540-2 - DOI - PubMed

Publication types

MeSH terms